149556-85-4

Basic information

• Product Name: 4-formyl-N-(pyridin-2-yl)benzenesulfonamide
• Synonyms: 4-formyl-N-(pyridin-2-yl)benzenesulfonamide
• CAS NO: 149556-85-4
• Molecular Weight: 262.289
• Mol File: 149556-85-4.mol

Chemical Properties

• CAS DataBase Reference: 4-formyl-N-(pyridin-2-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-formyl-N-(pyridin-2-yl)benzenesulfonamide(149556-85-4)
• EPA Substance Registry System: 4-formyl-N-(pyridin-2-yl)benzenesulfonamide(149556-85-4)

Safety Data

• Hazardous Substances Data: 149556-85-4(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 504-29-0 2-aminopyridine 
• 85822-16-8 4-formylbenzene-1-sulfonyl chloride 
• 69232-47-9 (4-(chlorosulfonyl)phenyl)methylene diacetate 

Downstream Products

• 149556-68-3 2-Hydroxy-5-[1-oxo-3-[4-[(2-pyridinylamino)sulfonyl]phenyl]-2-propenyl]benzoic acid 

Relevant articles and documents

5- OR 7-AZAINDAZOLES AS BETA-LACTAMASE INHIBITORS

The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacterial infection, alone or in combination with β-lactam antibiotics and/or other antibiotics and/or other β-lactamase inhibitors.

NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS

The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.